A new class of drugs

Inositec is building a pipeline of novel drugs based on IP6, initially targeting vascular calcification and CDI.  Inositune™ molecules have been fine-tuned to address specific therapeutic indications.

Calcification Inhibitors

Inositec is developing drug candidates based on IP6 that have been designed specifically to possess superior potency and pharmacokinetics that will provide significant patient benefit.

The build-up of calcium and/or phosphate in the blood can lead to mineral deposits, particularly in the vascular system. This is due to a loss in control of factors in the blood that regulate mineral balance in the body.

These deposits lead to a stiffening and/or occlusion of arterial walls, ultimately leading to:

  • stenosis
  • increased blood pressure
  • left ventricular hypertrophy
  • reduced coronary blood flow
  • compromised endothelial function
  • damage to the microcirculation in various organs

As a result, the proportion of cardiovascular events, as well as all-cause mortality, increases with progression of calcifications. These effects are particularly marked in patients with chronic kidney disease or diabetes.

There is a significant unmet need for a therapeutic agent capable of reducing pathological crystallization regardless of its root cause. To date, there is no approved therapy for treating calcification-dependent cardiovascular disease. The therapeutics developed by Inositec are being designed to potently inhibit the crystallization process in soft tissues and to display drug-like properties.

Addressing Clostridium difficile infection

Inostitec has discovered a series of orally active, small molecule compounds that irreversibly inhibit Clostridium difficile toxins.

The symptoms C. difficile infection (CDI) causes are mainly produced by two highly similar protein toxins (toxin A and toxin B) that are secreted by the bacterium once it arrives in the colon. Inhibiting the action of these toxins reduces inflammation and damage to the colon. Alleviating these symptoms also helps promote a more rapid regeneration of the intestinal microbiota. This could lead to reduced infection recurrence rates, since individuals with a healthy microbiota generally do not show symptoms from C. difficile carriage.

Strong differentiation from other therapeutic approaches to CDI treatment:

  • Novel and irreversible mechanism of action
  • Small molecules for oral administration
  • Non-antibiotic for no emergence of resistance
  • Toxin-targeted for rapid alleviation of symptoms, reduced intestinal damage and minimal infection recurrence through rapid restoration of gut flora
  • Low toxicity, low absorbance expected based on extensive data from IP6